Get started
Author

Thomas E. Boyd

Observed names: T. Boyd, T. E. Boyd, Thomas Boyd, Thomas E Boyd
Observed institutions: University of Vermont, Jagiellonian University, Roswell Park Comprehensive Cancer Center, Kaiser Permanente, The University of Texas MD Anderson Cancer Center, The University of Melbourne, Queen Mary University of London, Peter MacCallum Cancer Centre, Long Island Jewish Medical Center, University of Chicago, Instituto Argentino de Diagnóstico y Tratamiento, Kaiser Permanente Vallejo Medical Center, Duke Medical Center, North Medical Center, Pharmacyclics (United States), Stanford Medicine, Rocky Mountain Cancer Centers, Willamette Valley Cancer Institute and Research Center, The US Oncology Network, Virginia Mason Memorial, Weill Cornell Medicine, Cross Cancer Institute, University of Nebraska Medical Center, Stanford University
OpenAlex ID: A5081735534
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
2012 · Ranjana H. Advani, Joseph J. Buggy, et al. · Journal of Clinical Oncology · 1,142
PDF
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
2015 · Peter Hillmen, Tadeusz Robak, et al. · The Lancet · 345
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
2007 · Susan O'Brien, Joseph O. Moore, et al. · Journal of Clinical Oncology · 308
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
2015 · Heather H. Cheng, Colin C. Pritchard, et al. · European Urology · 266
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
2019 · Maria-Victoria Mateos, Hilary Blacklock, et al. · The Lancet Haematology · 259
PDF
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
2009 · Susan O'Brien, Joseph O. Moore, et al. · Journal of Clinical Oncology · 168
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
2018 · Rami Komrokji, Guillermo Garcia-Manero, et al. · The Lancet Haematology · 122
Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)
2013 · Peter Hillmen, Tadeusz Robak, et al. · Blood · 85
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
2018 · Tycel Phillips, Paul M. Barr, et al. · Investigational New Drugs · 82
PDF
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
2009 · Nicholas Di Bella, Raymond Taetle, et al. · Blood · 76
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
2014 · David A. Smith, Paul Conkling, et al. · Cancer Immunology Immunotherapy · 75
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
2016 · Giorgio Scagliotti, Jin Hyoung Kang, et al. · Investigational New Drugs · 74
A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma
2019 · Sumanta K. Pal, Andres Forero‐Torres, et al. · Cancer · 70
PDF
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases
2017 · Costantine Albany, Lawrence Einhorn, et al. · The Oncologist · 51
PDF
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
2015 · Christopher R. Cogle, Bart L. Scott, et al. · The Oncologist · 48
PDF
The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study
2010 · Nathan Fowler, Jeff Porte Sharman, et al. · Blood · 48
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
2012 · Nathan H Fowler, Ranjana H Advani, et al. · Blood · 44
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
2004 · Kanti R. Rai, Joseph O. Moore, et al. · Blood · 37
A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide ( ICE ) in patients with relapsed lymphoma
2013 · Lihua E. Budde, Michelle M. Zhang, et al. · British Journal of Haematology · 36
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
2012 · Steven E. Coutre, John P. Leonard, et al. · Blood · 35
Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
2013 · Eric Laille, Michael R. Savona, et al. · The Journal of Clinical Pharmacology · 34
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
2013 · Jacqueline Claudia Barrientos, Richard R. Furman, et al. · Journal of Clinical Oncology · 34
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
2011 · Jeff Sharman, Sven de Vos, et al. · Blood · 32
Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.
2010 · R. Advani, J. P. Sharman, et al. · Journal of Clinical Oncology · 32
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
2014 · Rami S Komrokji, Guillermo Garcia-Manero, et al. · Blood · 27
Works count: 67
Citation count: 3,919
H-index: 25
I10-index: 45
Year
Topic
Type